|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016017,
umls-concept:C0021368,
umls-concept:C0030705,
umls-concept:C0206461,
umls-concept:C0288672,
umls-concept:C0332293,
umls-concept:C0427579,
umls-concept:C0441509,
umls-concept:C0574032,
umls-concept:C0948089,
umls-concept:C1879547
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-2-4
|
|
pubmed:abstractText |
In acute coronary syndromes, the inflammation and the coagulation systems are activated, implying an impaired outcome. In addition to platelet inhibition, recent evidence suggests that the glycoprotein IIb/IIIa receptor inhibitor abciximab attenuates inflammation and coagulation activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Coagulation Factors,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Dalteparin,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrin,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/abciximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
147
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
267-74
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14760324-Aged,
pubmed-meshheading:14760324-Angina, Unstable,
pubmed-meshheading:14760324-Antibodies, Monoclonal,
pubmed-meshheading:14760324-Anticoagulants,
pubmed-meshheading:14760324-Biological Markers,
pubmed-meshheading:14760324-Blood Coagulation,
pubmed-meshheading:14760324-Blood Coagulation Factors,
pubmed-meshheading:14760324-C-Reactive Protein,
pubmed-meshheading:14760324-Dalteparin,
pubmed-meshheading:14760324-Double-Blind Method,
pubmed-meshheading:14760324-Electrocardiography,
pubmed-meshheading:14760324-Female,
pubmed-meshheading:14760324-Fibrin,
pubmed-meshheading:14760324-Fibrinolysis,
pubmed-meshheading:14760324-Humans,
pubmed-meshheading:14760324-Immunoglobulin Fab Fragments,
pubmed-meshheading:14760324-Inflammation,
pubmed-meshheading:14760324-Interleukin-6,
pubmed-meshheading:14760324-Male,
pubmed-meshheading:14760324-Middle Aged,
pubmed-meshheading:14760324-Platelet Aggregation Inhibitors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
|
|
pubmed:affiliation |
Department of Medical Sciences, Cardiology, Thoraxcenter, Academic Hospital, Uppsala, Sweden. stefan.james@akademiska.se
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
